Skip to main content
Presentation
≥156-week apremilast safety in psoriasis and psoriatic arthritis patients: pooled analysis of the ESTEEM and PALACE phase 3 trials. Australasian College of Dermatologists’ (ACD) Annual Scientific Meeting, Sydney, New South Wales, May 2017.
Australasian College of Dermatologists’ (ACD) Annual Scientific Meeting (2017)
  • J Crowley
  • J Wollenhaupt
  • Philip Mease, Providence St. Joseph Health
  • et.al.
Disciplines
Publication Date
May, 2017
Citation Information
J Crowley, J Wollenhaupt, Philip Mease and et.al.. "≥156-week apremilast safety in psoriasis and psoriatic arthritis patients: pooled analysis of the ESTEEM and PALACE phase 3 trials. Australasian College of Dermatologists’ (ACD) Annual Scientific Meeting, Sydney, New South Wales, May 2017." Australasian College of Dermatologists’ (ACD) Annual Scientific Meeting (2017)
Available at: http://works.bepress.com/philip-mease/305/